Literature DB >> 18844766

ASH position paper: treatment of hypertension in patients with diabetes-an update.

George L Bakris1, James R Sowers.   

Abstract

This report updates concepts on hypertension management in patients with diabetes. It focuses on clinical outcomes literature published within the last 3 years and incorporates these observations into modifications of established guidelines. While the fundamentals of treatment and goal blood pressures remain unchanged, approaches to specific patient-related issues has changed. This update focuses on questions such as what to do when a patient has an elevated potassium level when therapy is initiated and whether combinations of agents that block the renin-angiotensin system still be used. In addition, there are updates from trials, just published and in press, that focus on related management issues influencing cardiovascular outcomes in persons with diabetes. Last, an updated algorithm is provided that incorporates many of the new findings and is suggested as a starting point to achieve blood pressure goals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18844766      PMCID: PMC8673265          DOI: 10.1111/j.1751-7176.2008.00012.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  50 in total

Review 1.  New-onset diabetes and antihypertensive drugs.

Authors:  Giuseppe Mancia; Guido Grassi; Alberto Zanchetti
Journal:  J Hypertens       Date:  2006-01       Impact factor: 4.844

Review 2.  Antihypertensive therapy in the presence of proteinuria.

Authors:  Pantelis A Sarafidis; Nitin Khosla; George L Bakris
Journal:  Am J Kidney Dis       Date:  2007-01       Impact factor: 8.860

3.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

Review 4.  Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute.

Authors:  Barry L Carter; Paula T Einhorn; Michael Brands; Jiang He; Jeffrey A Cutler; Paul K Whelton; George L Bakris; Frederick L Brancati; William C Cushman; Suzanne Oparil; Jackson T Wright
Journal:  Hypertension       Date:  2008-05-26       Impact factor: 10.190

5.  Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.

Authors:  Tomas Berl; Lawrence G Hunsicker; Julia B Lewis; Marc A Pfeffer; Jerome G Porush; Jean-Lucien Rouleau; Paul L Drury; Enric Esmatjes; Donald Hricik; Marc Pohl; Itamar Raz; Philippe Vanhille; Thomas B Wiegmann; Bernard M Wolfe; Francesco Locatelli; Samuel Z Goldhaber; Edmund J Lewis
Journal:  J Am Soc Nephrol       Date:  2005-06-01       Impact factor: 10.121

6.  Effect of ramipril on the incidence of diabetes.

Authors:  Jackie Bosch; Salim Yusuf; Hertzel C Gerstein; Janice Pogue; Patrick Sheridan; Gilles Dagenais; Rafael Diaz; Alvaro Avezum; Fernando Lanas; Jeffrey Probstfield; George Fodor; Rury R Holman
Journal:  N Engl J Med       Date:  2006-09-15       Impact factor: 91.245

7.  Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.

Authors:  George Bakris; Mark Molitch; Ann Hewkin; Mark Kipnes; Pantelis Sarafidis; Kaffa Fakouhi; Peter Bacher; James Sowers
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

8.  Effect of spironolactone on blood pressure in subjects with resistant hypertension.

Authors:  Neil Chapman; Joanna Dobson; Sarah Wilson; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Journal:  Hypertension       Date:  2007-02-19       Impact factor: 10.190

9.  Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.

Authors:  Hans Ibsen; Kristian Wachtell; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Ying Wan
Journal:  J Hypertens       Date:  2004-09       Impact factor: 4.844

10.  Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

View more
  13 in total

Review 1.  Best strategies for hypertension management in type 2 diabetes and obesity.

Authors:  Darren M Allcock; James R Sowers
Journal:  Curr Diab Rep       Date:  2010-04       Impact factor: 4.810

2.  Determinants of isolated systolic hypertension among diabetic patients visiting the diabetic clinic at the Tamale Teaching Hospital, Northern Ghana.

Authors:  Richard Kd Ephraim; Abdul-Razak Saasi; Enoch O Anto; Prince Adoba
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

Review 3.  Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.

Authors:  Adam Whaley-Connell; Megan S Johnson; James R Sowers
Journal:  Prog Cardiovasc Dis       Date:  2010 Mar-Apr       Impact factor: 8.194

4.  Genome-wide linkage screen for systolic blood pressure in the Veterans Administration Genetic Epidemiology Study (VAGES) of Mexican-Americans and confirmation of a major susceptibility locus on chromosome 6q14.1.

Authors:  Sobha Puppala; Dawn K Coletta; Jennifer Schneider; Shirley L Hu; Vidya S Farook; Thomas D Dyer; Rector Arya; John Blangero; Ravindranath Duggirala; Ralph A DeFronzo; Christopher P Jenkinson
Journal:  Hum Hered       Date:  2011-02-05       Impact factor: 0.444

5.  Type of β-blocker use among patients with versus without diabetes after myocardial infarction.

Authors:  Suzanne V Arnold; John A Spertus; Kasia J Lipska; David E Lanfear; Fengming Tang; Anna Grodzinsky; Darren K McGuire; M Odette Gore; Abhinav Goyal; Thomas M Maddox; Mikhail Kosiborod
Journal:  Am Heart J       Date:  2014-06-09       Impact factor: 4.749

Review 6.  The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress.

Authors:  Camila Manrique; Guido Lastra; Michael Gardner; James R Sowers
Journal:  Med Clin North Am       Date:  2009-05       Impact factor: 5.456

7.  Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes.

Authors:  Luis M Ruilope
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-09-23       Impact factor: 3.738

8.  ADVANCE: blood pressure lowering in diabetes.

Authors:  Anushka Patel; John Chalmers; Stephen MacMahon; Bruce Neal
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-02       Impact factor: 3.738

9.  Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.

Authors:  Raymond R Townsend; Alan D Forker; Vaishali Bhosekar; Anthony Yadao; Deborah L Keefe
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-11       Impact factor: 3.738

10.  Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus.

Authors:  Dean J Kereiakes; Joel M Neutel
Journal:  Drugs R D       Date:  2011-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.